|
1）Thiery JP, Sleeman JP. Complex networkes orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Bio. 2006; 7: 131-42
|
|
|
|
|
2）Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54
|
|
|
|
|
3）Derynck R, Zhang YE, Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425: 577-84
|
|
|
|
|
4）Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-15
|
|
|
|
|
|
5）Huang S, Hölzel M, Knijnenburg T, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 2012; 151: 937-50
|
|
|
|
|
|
6）Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44: 852-60
|
|
|
|
|
|
7）Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10: 593-601
|
|
|
|
|
|
8）Chang C, Chao C, Xia W, et al. p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011; 13: 317-23
|
|
|
|
|
|
9）Shintani Y, Okimura A, Sato K, et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 2011; 92: 1794-804
|
|
|
|
|
|
10）Ren J, Chen Y, Song H, et al. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2013; 114: 1395-403
|
|
|
|
|
|
11）Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8
|
|
|
|
|
|
12）Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8
|
|
|
|
|
|
13）Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-42
|
|
|
|
|
|
14）Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-46
|
|
|
|
|
|
15）Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005; 11: 8686-98
|
|
|
|
|
|
16）Miyanaga A, Gemma A, Ando M, et al. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treatedwith gefitinib. Oncol Rep. 2008; 19: 377-83
|
|
|
|
|
|
17）Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009; 63: 219-26
|
|
|
|
|
|
18）Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. 2011; 6: 1152-61
|
|
|
|
|
|
19）Kim HR, Kim WS, Choi YJ, et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 2013; 7: 1093-102
|
|
|
|
|
|
20）Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66: 944-5
|
|
|
|
|
|
21）Shien K, Toyooka S, Yamamoto H, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013; 73: 3051-61
|
|
|
|
|
|
22）Kitamura K, Seike M, Okano T, et al. MiR-134/487b/655 cluster regulates TGF-β-inducedepithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lungadenocarcinoma cells. Mol Cancer Ther. 2014; 13: 444-53
|
|
|
|
|
|
23）Cufí S, Bonavia R, Vazquez-Martin A, et al. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep. 2013; 3: 2459
|
|
|
|
|
|
24）Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010; 9: 4461-8
|
|
|
|
|
|
25）Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014; 20: 2714-26
|
|
|
|
|